Thaum Lub Ob Hlis 12, 2026, Lub Chaw Saib Xyuas Kev Tshuaj Xyuas Tshuaj (CDE) ntawm Tuam Tshoj Lub Chaw Tswj Xyuas Khoom Siv Kho Mob Hauv Tebchaws tau tshaj tawm thaum Lub Ob Hlis 4 tias ENHERTU® (trastuzumab deruxtecan) tau raug pom zoo rau kev suav nrog hauv Breakthrough Therapy Program rau kev siv ua kev kho mob adjuvant rau cov neeg laus uas muaj HER2-zoo mob qog noj ntshav thaum ntxov uas muaj cov kab mob invasive tom qab neoadjuvant anti-HER2 kev kho mob. Qhov kev txiav txim siab no yog raws li cov ntaub ntawv txaus nyiam los ntawm DESTINY-Breast05 Theem III kev tshawb fawb, nthuav tawm ntawm 2025 ESMO Congress, uas tau qhia tias ENHERTU txo qhov kev pheej hmoo ntawm kev muaj sia nyob tsis muaj kab mob (IDFS) lossis kev tuag los ntawm 53% piv rau T-DM1.
ENHERTU (trastuzumab deruxtecan; fam-trastuzumab deruxtecan-nxki hauv Tebchaws Meskas xwb) yog HER2 directed ADC. Tsim los ntawm kev siv Daiichi Sankyo's proprietary DXd ADC Technology, ENHERTU yog tus thawj coj ADC hauv oncology portfolio ntawm Daiichi Sankyo thiab yog qhov kev pab cuam siab tshaj plaws hauv AstraZeneca's ADC scientific platform. ENHERTU muaj HER2 monoclonal antibody txuas nrog ntau yam topoisomerase I inhibitor payloads (ib qho exatecan derivative, DXd) ntawm tetrapeptide-based cleavable linkers.
DESTINY-Breast05 yog ib qho kev sim thoob ntiaj teb, ntau lub chaw, randomized, qhib-daim ntawv lo, theem 3 ntsuam xyuas qhov ua tau zoo thiab kev nyab xeeb ntawm ENHERTU (5.4 mg / kg) piv rau trastuzumab emtansine (T-DM1) rau cov neeg mob uas muaj mob qog noj ntshav mis HER2 zoo thaum ntxov nrog cov kab mob tseem ceeb hauv lub mis lossis cov qog ntshav axillary tom qab kev kho mob neoadjuvant thiab muaj kev pheej hmoo siab ntawm kev rov tshwm sim. Kev pheej hmoo siab ntawm kev rov tshwm sim tau txhais tias yog kev nthuav qhia nrog mob qog noj ntshav tsis tuaj yeem phais (ua ntej kev kho mob neoadjuvant) lossis cov qog ntshav axillary zoo tom qab kev kho mob neoadjuvant.
Cov ntaub ntawv tseem ceeb los ntawm kev tshawb fawb DESTINY-Breast05:
- Kev Muaj Sia Nyob Tsis Muaj Kab Mob (IDFS): Tus nqi peb xyoos IDFS yog 92.4% hauv ENHERTU piv rau 83.7% hauv pawg tswj (T-DM1), uas sawv cev rau kev txo qis 53% ntawm kev pheej hmoo (HR = 0.47).
- Kev Ciaj Sia Tsis Muaj Kab Mob (DFS): Tus nqi DFS peb xyoos yog 92.3% hauv pawg ENHERTU piv rau 83.5% hauv pawg tswj, kuj qhia txog kev txo qis kev pheej hmoo 53% (HR = 0.47).
- Kev Pheej Hmoo Rov Qab Los Dua Deb (DRFI): Txo los ntawm 51%, nrog rau peb xyoos DRFI ntawm 93.9% piv rau 86.1%.
- Kev Pheej Hmoo ntawm Kev Kis Kab Mob Rau Lub Hlwb (BMFI): Txo los ntawm 36%, nrog rau peb xyoos BMFI tus nqi ntawm 97.6% piv rau 95.8%.
Lub Chaw Haujlwm Thoob Ntiaj Teb ntawm Tsev Kho Mob Cancer Beijing Southern Suburb tau mob siab rau kev pabcuam cov neeg mob txawv teb chaws, muab kev txhawb nqa ntau hom lus, kev them nqi ncaj qha nrog kev pov hwm thoob ntiaj teb, kev pabcuam tus kheej rau cov neeg mob, thiab kev pabcuam sib tham hauv xov tooj. Rau cov neeg mob uas muaj mob qog noj ntshav mis HER2-positive, Lub Chaw Haujlwm Thoob Ntiaj Teb muab pab pawg kws kho mob qog noj ntshav laus los tsim cov phiaj xwm kho mob adjuvant rau tus kheej.
Tham nrog tam sim no kom tau txais kev ntsuam xyuas kev kho mob:
Xov Tooj Pab Neeg Mob Thoob Ntiaj Teb: 400-880-3716 (kev pab cuam 24 teev ob hom lus, Suav/Lus Askiv)
WeChat Kab Ncaj Qha: 17801183037
Official Email ①: 100085_010@163.com
Backup Email ②: myimmnet@163.com
Txawm koj yog tus neeg mob tshiab uas tab tom kuaj pom tias muaj mob tom qab kev kho mob neoadjuvant, lossis tus neeg mob uas tau phais thiab tab tom xav txog kev kho mob adjuvant, pab pawg neeg ntawm Lub Tsev Haujlwm Thoob Ntiaj Teb tuaj yeem ua tiav kev tshuaj xyuas cov ntaub ntawv kho mob ua ntej thiab muab cov lus qhia sau ntawv rau kev kho mob.
Lub sijhawm tshaj tawm: Lub Ob Hlis-12-2026